Jackson Square Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Jackson Square Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$407K	Hold	527	–	–	0.09%	103
2025 Q4	$407K	Buy	+527	New	+$358K	0.08%	118
2020 Q4	–	Sell	-23	Closed	-$13K	–	291
2020 Q3	$13K	Hold	23	–	–	0.01%	252
2020 Q2	$14K	Sell	23 -2	-8%	-$1.14K	0.01%	226
2020 Q1	$12K	Buy	25 +2	+9%	+$825	0.01%	207
2019 Q4	$9K	Buy	+23	New	+$7.74K	0.01%	268

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jackson Square Capital's REGN Position: Q1 2026 in Review

Jackson Square Capital held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 527 shares worth $407K. The position accounts for 0.09% of the portfolio, ranked #103.

Jackson Square Capital first reported a position in REGN in Q4 2019 and has held it in 6 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Jackson Square Capital held 527 shares of Regeneron Pharmaceuticals worth $407K as of Q1 2026.
Jackson Square Capital left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
Regeneron Pharmaceuticals made up 0.09% of Jackson Square Capital's portfolio in Q1 2026, its #103 holding.
Jackson Square Capital first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 6 quarters since.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Jackson Square Capital's 13F filing for Q1 2026, filed 13 Apr 2026.